vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $53.00 Consensus PT from Brokerages

vTv Therapeutics Inc. (NASDAQ:VTVT) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $53.00.

A number of equities research analysts have recently issued reports on VTVT shares. HC Wainwright reissued a “buy” rating and issued a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Evercore assumed coverage on shares of vTv Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $44.00 target price on the stock. TD Cowen initiated coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating on the stock. BTIG Research reissued a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Monday, December 29th.

vTv Therapeutics Stock Up 3.6%

VTVT opened at $37.28 on Friday. The firm has a 50-day moving average price of $35.58 and a 200-day moving average price of $30.43. vTv Therapeutics has a twelve month low of $14.00 and a twelve month high of $44.00. The company has a market capitalization of $146.81 million, a price-to-earnings ratio of -11.13 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.51. The business had revenue of ($0.02) million during the quarter.

Hedge Funds Weigh In On vTv Therapeutics

Several institutional investors have recently modified their holdings of VTVT. Goldman Sachs Group Inc. bought a new stake in vTv Therapeutics in the 4th quarter worth approximately $221,000. 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics during the fourth quarter worth approximately $731,000. Geode Capital Management LLC lifted its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP boosted its stake in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares in the last quarter. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.